CAR T Therapy: The Cancer Treatment That Might Reset Autoimmune Disease

## From Cancer to Autoimmunity

CAR T cell therapy was designed to kill cancer. Extract a patient's T cells, genetically engineer them to recognize cancer-specific proteins (chimeric antigen receptors, or CARs), and reinfuse them. The modified cells hunt and destroy cancer. It works — remission rates of 80%+ in certain blood cancers.

Now researchers are asking: what if we engineer CAR T cells to destroy the immune cells that cause autoimmune disease instead?

## How It Works for Autoimmunity

In autoimmune diseases (lupus, multiple sclerosis, rheumatoid arthritis), the immune system attacks the body's own tissues. Specific B cells produce the autoantibodies that drive the damage. The insight: CAR T cells can be programmed to target and eliminate these specific B cells, effectively "resetting" the immune system.

A 2026 study reported in Knowable Magazine showed that CAR T therapy produced drug-free remission in severe lupus patients. The engineered T cells eliminated the autoreactive B cell population, after which the body regenerated healthy B cells — without the autoimmune programming.

## The Numbers (Early but Striking)

| Condition | Patients | Remission Rate | Follow-up |
|-----------|---------|---------------|-----------|
| Severe SLE (lupus) | 15 | 87% | 12-24 months |
| Systemic sclerosis | 8 | 75% | 12 months |
| Myasthenia gravis | 5 | 80% | 6-12 months |

These are tiny sample sizes. The field is in Phase I/II trials. But the 87% remission rate in lupus — a disease that typically requires lifelong immunosuppression — is the kind of signal that attracts serious capital.

## The Risks Are Not Small

CAR T therapy has killed people. Cytokine release syndrome (CRS) — an overwhelming immune response — is the main danger. Neurotoxicity is the second. The risks are acceptable in terminal cancer. In autoimmune disease, where patients can live decades with conventional treatment, the risk-benefit calculus is fundamentally different.

The 2026 approach uses lower CAR T cell doses and different genetic constructs to reduce CRS risk. But the safety data isn't mature.

## What Changes If This Works

If CAR T proves safe and effective for autoimmunity at scale, the economics of drug development shift. Current autoimmune treatments (Humira, Enbrel) cost $30,000-$80,000 per year — for life. A $400,000 one-time CAR T infusion that produces permanent remission is actually cheaper over a patient's lifetime.

The obstacle is manufacturing. CAR T is personalized: each dose is made from the patient's own cells. Scaling this to millions of autoimmune patients (vs. tens of thousands of cancer patients) requires manufacturing advances that don't exist yet.

CAR T Therapy: The Cancer Treatment That Might Reset Autoimmune Disease

// COMMENTS

ON THIS PAGE